Relevant TAAs in hematologic malignancies include CD19 in acute B cell lymphoblastic leukemia (B-ALL); BCMA, GPRC5D (G Protein–coupled Receptor class C group 5 member D), FCRH5 (Fc receptor homologs 5) and CD38 in multiple myeloma (MM); CD19, CD20 and CD30 in lymphomas; and CD33 and CD123 in acute myeloid leukemia (AML). This evidence concerns the gene CD19 and AL amyloidosis.